AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 31 min read$RSSS

Cohen Sefton sold (to issuer) $625K of RSSS

Cohen Sefton (Chief Revenue Officer) sold (to issuer) 284,000 shares of Research Solutions, Inc. (RSSS) at $2.20 ($0.62M total) on 2026-07-31.

Original reporting
SEC EDGAR · Cohen Sefton
Published Aug 3, 2026, 1:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 3, 2026, 1:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RSSS
Neutral
medium confidence
Mentioned
$RSSS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RSSSNeutralLow
01

Why it matters

Traders may monitor for additional insider transactions or corroborating signals, but the text contains no operational, financial, or regulatory catalyst beyond the sale itself.

02

Market read

A CRO insider sale to the issuer of $624,800 is newly disclosed, which can slightly pressure sentiment but lacks fundamental follow-through in the provided text.

03

What to watch

The filing does not state the reason for sale, and it explicitly notes no pre-arranged 10b5-1 plan, which can increase interpretive noise rather than confirm a bearish thesis.

Relevance 5/10Novelty 5/10Timing: filed 2026-08-03, transaction dated 2026-07-31

Background

The article is a SEC Form 4 insider transaction disclosure for Research Solutions, Inc. (RSSS).

Company-level read

Ticker impact

$RSSSNeutralMedium confidence
Context

Research Solutions, Inc. disclosed a Form 4 showing CRO Cohen Sefton sold 284,000 shares at $2.20 on 2026-07-31.

Expected impact

Likely limited, short-lived sentiment impact unless follow-on selling or other disclosures emerge.

Evidence & confidence

The filing is primary-source and time-stamped, but the transaction is an insider sale without accompanying company news, guidance, or legal/financial event in the text.

Market effects

Sector

No sector-level implications are provided; this is company-specific insider activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales to the issuer can be routine liquidity or tax-related and may not signal reduced confidence, especially without any other negative company developments.

Key entities

  • issuer
    Research Solutions, Inc.

    Company filing the Form 4 for insider transaction activity.

  • insider
    Cohen Sefton

    Chief Revenue Officer who sold shares to the issuer.

  • filing
    SEC Form 4

    Primary disclosure of insider trading transaction details.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RSSS insider trading history →

Related articles

SEP 9
$RSSSMed

Research Solutions Reports Fourth Quarter and Fiscal Year 2026 Results

Research Solutions (RSSS) reported fiscal Q4 2026 revenue of $12.1M, down from $12.4M YoY. Full-year revenue was $48.3M, slightly below prior year's $49.1M. Net income rose to $2.8M for the year, up from $1.3M. B2B ARR grew 14% YoY to $16.2M, with AI-related ARR up 125% sequentially. Gross margin improved to 53% in Q4 and 51.9% for the year, driven by platform revenue growth.

prnewswire.com2 min
SEP 9
$RSSSMed

Research Solutions Reports Fourth Quarter and Fiscal Year 2026 Results

Research Solutions, Inc. (RSSS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Research Solutions Reports Fourth Quarter and Fiscal Year 2026 Results Reports Record Fiscal Year Net Income of $2.8 Million, 14% YoY B2B ARR Increase and ARR of $22.5 Million HENDERSON, Nev., September 9, 2026 — Research Solutions, Inc. (NASDAQ

SEC EDGAR 8-K2 min
NOV 3
$ASPEMedAI 8/10

ARCH Venture Fund X, L.P. (CRANDELL KEITH, Burow Kristina) purchased $18.0M of ASPE (indirect holdings)

ARCH Venture Fund X, L.P. purchased 1,200,000 indirectly-held shares of Aspen Neuroscience, Inc. (ASPE) at $15.00 ($18.00M total) on 2026-11-02. Filed jointly with ARCH Venture Fund X Overage, L.P. (10% owner), ARCH Venture Partners X, L.P. (10% owner), ARCH Venture Partners X Overage, L.P. (10% owner), ARCH Venture Partners X, LLC (10% owner), CRANDELL KEITH (10% owner), Burow Kristina (10% owner), GILLIS STEVEN (10% owner) and NELSEN ROBERT (10% owner).

SEC EDGAR1 min
NOV 3
$ASPELow

ARCH Venture Fund X, L.P. (CRANDELL KEITH, Burow Kristina) purchased $2.0M of ASPE

ARCH Venture Fund X, L.P. purchased 133,333 shares of Aspen Neuroscience, Inc. (ASPE) at $15.00 ($2.00M total) across 2 trades on 2026-11-02. Filed jointly with ARCH Venture Fund X Overage, L.P. (10% owner), ARCH Venture Partners X, L.P. (10% owner), ARCH Venture Partners X Overage, L.P. (10% owner), ARCH Venture Partners X, LLC (10% owner), CRANDELL KEITH (10% owner), Burow Kristina (10% owner), GILLIS STEVEN (10% owner) and NELSEN ROBERT (10% owner).

SEC EDGAR1 min